Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways.
Wang G, Ma C, Chen K, Wang Z, Qiu H, Chen D, He J, Zhang C, Guo D, Lai B, Zhang S, Huang L, Yang F, Yuan J, Chen L, He W, Xu J.
Wang G, et al. Among authors: ma c.
Front Pharmacol. 2022 Jan 20;12:810322. doi: 10.3389/fphar.2021.810322. eCollection 2021.
Front Pharmacol. 2022.
PMID: 35126144
Free PMC article.